Articles tagged with Spike Glycoprotein
Researchers discovered a 'sticky' molecule, P-selectin, that can cause blood clots and organ failure during COVID-19. A new mRNA therapy that drives P-selectin expression provides broad protection against coronavirus infection.
Researchers developed CeSPIACE, a 39-amino-acid peptide drug candidate that binds to the spike protein, blocking viral entry. It demonstrates strong binding to major SARS-CoV-2 variants and shows efficacy against multiple strains in vivo and in vitro experiments.
Researchers discovered a novel coronavirus in bats in Brazil with similarities to the Middle East respiratory syndrome virus. The five bats belonged to two species and showed significant genetic diversity, prompting experiments to determine whether it can infect humans.
Researchers from Osaka Metropolitan University have developed a method to detect coronavirus spike proteins quickly and selectively using a light-induced immunoassay. The technique uses a milliwatt-level laser and can complete the entire process in under 5 minutes.
A new study published in Microorganisms highlights the importance of small molecule drugs that target the unchanging parts of the SARS-CoV-2 virus. The research suggests that these stable targets could provide a consistent and reliable treatment option for COVID-19, even as vaccines are updated to address changing viral strains.
Researchers found a specific deletion in the spike protein that enhances the virus' ability to infect brains of mice, which could help understand 'long COVID' and develop treatments. The study suggests viruses with this deletion can traffic from the lung to the brain, leading to neurological symptoms.
Researchers at UVA Health discovered a potential explanation for long COVID symptoms by identifying 'abzymes' that act like enzymes regulating important bodily functions. This discovery could lead to new treatments targeting these rogue antibodies to alleviate acute effects of COVID-19 and its complications.
Researchers found that T cells can reshape their memory and maintain diversity against COVID-19 variants in response to successive mRNA vaccinations. The study revealed a shift among clonotypes, with a change from early responders to main responders after the second shot, suggesting a new dominant population of effector-memory T cells.
A new study from Tulane University found that perlecan LG3, a protein commonly found in blood vessels and the brain, forms a stable bond with the COVID spike protein, enhancing the virus's ability to bind with cells. This discovery may lead to new forms of treatment or prevention for COVID-19.
Research reveals memory T cells formed after Omicron breakthrough infection provide enhanced immunity against future variants. The study suggests the immune system adapts to combat emerging strains, leading to higher chances of inducing memory T cell defenses.
Researchers designed a synthetic antigen with high expression levels and stability, offering potential for quick adaptation to new variants. The vaccine candidate triggered strong immune response in animal models and showed enhanced protective efficacy.
The BA.2.86 omicron subvariant can infect human lung cells more efficiently than previous omicron variants, raising concerns about potential severe disease symptoms. While bivalent mRNA vaccines can neutralize BA.2.86, the efficiency is reduced, emphasizing the importance of getting a newer booster vaccine.
Researchers at Utrecht University have uncovered a sophisticated mechanism by which coronavirus spike proteins can be activated for cell entry. Sugar binding induces opening of the spike protein and exposure of the receptor binding domain, required for subsequent entry steps.
Researchers have developed a synthetic peptide that could help reduce vascular problems associated with acute respiratory distress syndrome in COVID-19. The peptide, called TIP, works by binding to a subunit of the epithelial sodium channel, which helps maintain barrier function and prevent damage from viral proteins.
A new SARS-CoV-2 variant Eris has been detected, showing an advantage in evading neutralizing antibodies and increasing infectivity. The study found that Eris is less effectively neutralized by antibodies present in the blood of vaccinated individuals or those with a previous infection.
New SARS-CoV-2 variants, such as BQ.11 and XBB.1.5, bind to cells more tightly and evade antibodies more efficiently than earlier variants, allowing reinfections and breakthrough infections. Previous infection or vaccination can generate antibodies that recognize some proteins on newer variants, reducing the risk of serious illness.
Researchers show that a single virus binds to a single receptor, opening the door for efficient infection. ACE2 receptors are present singly in the membrane, contradicting previous hypotheses about multiple receptor binding.
A small molecule discovered by University of Houston researchers could potentially shorten the course of SARS-CoV-2 infection, offering a new alternative treatment option for COVID-19. The compound, CD04872SC, has shown promise in neutralizing the virus and its variants Delta and Omicron.
Researchers have identified a highly conserved region of the SARS-CoV-2 spike protein that could be targeted to boost human antibody responses against any coronavirus. The discovery could aid the development of more powerful antibody drugs and vaccines against COVID-19 and emerging coronaviruses.
Researchers at Arizona State University describe an innovative therapy using transient expression in tobacco plants to produce a monoclonal antibody against SARS-CoV-2. This class 4 mAb provides key advantages over existing treatments, including mutation resistance and universal protection against emerging variants.
Researchers have found that the naturally occurring amino acid ALA can reduce the expression of ACE2 on cell membranes, potentially lowering SARS-CoV-2's infectious capabilities. The study also reveals an underlying mechanism involving the production of heme, which is boosted by co-administering ALA with an iron source.
A study found that the Omicron variant can dodge immune responses with just one or two dramatic mutations, while combinations of many mutations enable it to escape specific antibodies. The research suggests trade-offs between escaping immunity and maintaining infective capacity.
Scientists have identified small molecules that can target the 'Achilles' heel' of SARS-CoV-2, a less mutation-prone segment of the spike protein. These compounds could serve as a starting point for developing effective treatments for COVID-19.
Scientists have identified a new class of 'bivalent' antibodies that can bind to two viral targets at once, neutralizing multiple Omicron variants. These potent antibodies retain efficacy against early SARS-CoV-2 variants and several later Omicron sub-lineages.
Researchers found a genetic alteration in the SARS-CoV-2 spike protein that redirects the virus into a storage compartment within cells, reducing its surface exposure. This change may affect the immune system's ability to identify and kill infected cells.
A study by Mass General Brigham found elevated levels of spike protein, increased cytokines, and troponin in the blood of 16 adolescents and young adults who developed myocarditis after COVID mRNA vaccination. The researchers also discovered no differences in antibody production or auto-antibodies between cases and controls.
A new study suggests that the SARS-CoV-2 spike protein contributes to vascular leak, a dangerous release of fluids from blood vessels leading to respiratory failure. Researchers believe blocking this pathway could help prevent severe COVID-19 symptoms and shed light on other emerging infectious diseases.
Researchers used computer simulations to show that SARS-CoV-2 variants can attach to host cells in both bats and humans using their spike proteins. The study's findings suggest a significant risk of mammalian cross-species infectivity, contradicting initial expectations of reduced transmission.
Researchers found that antibodies against one of the two main domains of the SARS-CoV-2 viral entry machinery elicit a broad antibody response against many variants. This suggests strategies for clinical development of variant-resistant vaccines.
A Brazilian team developed an electrochemical immunosensor to detect SARS-CoV-2 antibodies, achieving 88.7% sensitivity and 100% specificity in just five minutes. The device can be adapted for other diseases and has potential for monitoring seroconversion and seroprevalence.
Researchers have identified a tailor-made pocket feature in the spike glycoproteins of deadly coronaviruses, including SARS-CoV-2, MERS, and Omicron. This finding could lead to the development of a pan-coronavirus treatment that exploits this pocket feature to stop virus infectivity.
A team from UNIGE has revealed the existence of a hidden 'pocket' on the surface of the non-structural protein Nsp1, which could be used to develop new treatments against Covid-19. This discovery paves the way for innovative therapies targeting the Nsp1 protein and its potential application against other coronaviruses.
Researchers found two Korean native plants' saponins inhibit SARS-CoV-2 entry into cells by blocking membrane fusion. These compounds show promise in treating COVID-19, especially for asymptomatic cases.
A study found that specific N-glycans on the SARS-CoV-2 spike protein regulate its development and functional maturation. This is crucial for viral entry into host cells. Researchers highlight N-linked glycans as potential drug targets for COVID-19.
Cell membranes facilitate viral infection by allowing spike proteins to bind and enter cells. The study identifies the role of cell membranes in SARS-CoV-2 variant infections, providing insights into potential therapeutic targets.
Researchers have identified two effective antibodies that neutralize all known strains of COVID-19, including Delta and Omicron variants. These breakthrough antibodies could eliminate the need for repeated booster vaccinations and strengthen immune systems, especially in at-risk populations.
Researchers at UBC have discovered a key vulnerability across all major COVID-19 variants that can be targeted by neutralizing antibodies. The 'master key' identified is the antibody fragment V H Ab6, which effectively neutralizes SARS-CoV-2 by attaching to the epitope on the spike protein.
Researchers at the Francis Crick Institute have made significant progress in designing a pan-coronavirus vaccine that targets the S2 area of the spike protein, offering protection against multiple coronaviruses and potential future pandemics. The study found that antibodies targeting this area can neutralize a range of coronaviruses, i...
The SARS-CoV-2 spike protein activates the natural immune response in heart muscle cells, causing damage and inflammation. The study found that the spike protein also caused hypertrophic remodeling and cardiac dysfunction in lab mice, highlighting a novel, ACE2-independent pathological role of the virus.
A study by Goethe University Frankfurt found that antibodies against Omicron variants BA.1 and BA.2 decline rapidly, even after a second vaccination or booster shot, offering limited protection against infection.
Researchers used virus-like particles to identify mutations in Omicron that make it more infectious and escape antibodies. The study found that mutations in the nucleocapsid protein are crucial for enhancing spread, highlighting potential new vaccine targets.
A new study suggests that current vaccine boosters intensify protections against serious infection caused by Omicron subvariants. The research found that booster doses bring neutralizing antibodies to appreciable levels against all Omicron subvariants, consistent with other evidence of expanded memory B cells and antibody production.
MU researchers have identified specific mutations in the Omicron variant's spike protein that help it evade existing antibodies from vaccines or previous COVID-19 infections. These findings can inform developers of COVID-19 treatments and vaccines, which may need to target different parts of the virus to produce effective outcomes.
Scientists at UC Davis have successfully produced COVID-19 antibodies in hen eggs, which may be used as a preventative measure or treatment for people exposed to the disease. The antibodies, similar to those found in human blood, were shown to neutralize the virus effectively.
A new study found that the fourth COVID-19 vaccine reduces the risk of death among elderly individuals in long-term care facilities by 72%. The study, which included approximately 40,000 residents, also showed a significant reduction in hospitalizations and infections.
Researchers created an atomic-level computational model of the COVID-19 spike protein, finding that human cell modifications increase its flexibility and mobility. The study suggests that these modifications can enhance virus infectivity and immune avoidance.
Researchers analyzed antibodies to internal and surface proteins of SARS-CoV-2, finding that profiles of internal proteins predicted survival outcomes as well as those for surface proteins. The study suggests targeting other parts of the virus could enhance COVID-19 vaccines and therapies.
Scientists employed artificial intelligence to determine the 3D structure of the VP8* B domain in group B rotavirus, a crucial step towards understanding its interaction with host cells and developing new treatments. The newly described structure reveals unique sugar recognition capabilities, distinct from other rotaviruses.
A new study by the University of Colorado Anschutz Medical Campus explores the effects of multiple mutations in SARS-CoV-2 variants. The findings suggest that certain mutations work together to improve virus fitness, making it challenging for antibody treatments to neutralize new variants.
Researchers at Brigham and Women's Hospital studied mRNA vaccine safety in pregnant women, finding no Spike protein expression in placentas. The study provides further evidence of mRNA vaccine safety, supporting expanded vaccination efforts for vulnerable populations.
A recent study published in Frontiers in Microbiology reveals the correlation between sugar identity and flexibility in SARS-CoV-2 spike glycoprotein. The researchers used high-resolution cryo-electron microscopy and computer simulation to understand the impact of glycans on antibody recognition and protein shielding.
Scientists found a connection between the SARS-CoV-2 virus and the production of misfolded proteins called amyloids, which can cause complex symptoms and damage in organs such as the heart and kidneys. The researchers' discovery may help explain why COVID-19 often affects multiple parts of the body.
The Delta variant of SARS-CoV-2 can attach to copies of itself, forming larger clumps of viral particles. This unique binding property may have contributed to its rapid spread. The study found that the Delta spike protein enables the virus to bind to cells and form aggregations, increasing the chances of infection.
Researchers characterized viral protein binding to sialic acids on animal and human coronaviruses, revealing host-specific patterns. This adaptation enables coronaviruses to quickly jump species, driving cross-species transmission.
Researchers from Goethe University and University of Kent found aprotinin effective against SARS-CoV-2 variants, including Delta and Omicron, by preventing virus entry into host cells. A recent phase III clinical study demonstrated the treatment reduced hospital stays by five days.
Researchers at the University of Huddersfield have identified a key mechanism by which the coronavirus causes inflammation in the brain's immune cells, potentially explaining some symptoms experienced by COVID-19 patients. The study suggests that adequate funding is needed to further develop this research and its potential applications.
A new study from Karolinska Institutet and Helmholtz Center Munich found that macrophages show altered inflammatory and metabolic expression several months after mild COVID-19. Even though most individuals were symptom-free, their immune systems were more sensitive than those of healthy counterparts.
The investigational vaccine targets both the spike and nucleocapsid proteins, producing neutralizing antibodies and inducing T cell responses against SARS-CoV-2. COH04S1 is being studied in Phase 2 trials for immunocompromised patients and as a booster for healthy adult volunteers.
Scientists have developed an unusual toolbox using quantum physics and molecular mapping to monitor SARS-CoV-2's spike protein. The approach aims to improve diagnosis, variant risk assessment, and treatment by identifying hotspots in the genome where highly-infectious mutations emerge.
Mutations in SARS-CoV-2's spike protein can resist neutralizing antibodies and therapeutics, highlighting the need for improved vaccines and treatments. The study mapped out these 'escape variants' to understand their molecular mechanisms.